Plasminogen activator inhibitor-1 and asthma: Role in the pathogenesis and molecular regulation

Clinical and Experimental Allergy

Volumn 39, Issue 8, 2009, Pages 1136-1144

  Ma, Z ^a   Paek, D ^a   Oh, C K ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UPSTREAM STIMULATORY FACTOR 1;

ALLELE; ANIMAL CELL; ANIMAL TISSUE; ASTHMA; BRONCHUS HYPERREACTIVITY; DISEASE SEVERITY; E BOX ELEMENT; FIBRINOLYSIS; GENE; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOPATHOGENESIS; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PAI 1 GENE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION;

ALLELES; ASTHMA; GENOTYPE; HUMANS; MAST CELLS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 67650451135     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2009.03272.x     Document Type: Review

References (89)

1. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 2007 12 : 2957 66.
2. Oh CK, Ariue B, Alban RF, Shaw B, Cho SH. PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun 2002 294 : 1155 60.
3. Wagers SS, Norton RJ, Rinaldi LM, Bates JH, Sobel BE, Irvin CG. Extravascular fibrin, plasminogen activator, plasminogen activator inhibitors, and airway hyperresponsiveness. J Clin Invest 2004 114 : 104 11.
4. Kelly MM, Leigh R, Bonniaud P et al. Epithelial expression of profibrotic mediators in a model of allergen-induced airway remodeling. Am J Respir Cell Mol Biol 2005 32 : 99 107. (Pubitemid 40189691)
5. Kucharewicz I, Mogielnicki A, Kasacka I, Buczko W, Bodzenta-ukaszyk A. Plasmin System regulation in an ovalbumin-induced rat model of asthma. Int Arch Allergy Immunol 2008 147 : 190 6.
6. Lee Chung H, Kim SY, Kim SG. Vascular endothelial growth factor and plasminogen activator inhibitor-1 in children with recurrent early wheeze. J Allergy Clin Immunol 2007 119 : 1541 2.
7. Cho SH, Tam SW, Demissie-Sanders S, Filler SA, Oh CK. Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. J Immunol 2000 165 : 3154 61.
8. Xiao W, Hsu YP, Ishizaka A, Kirikae T, Moss RB. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest 2005 128 : 2316 26.
9. Kowal K, Bodzenta-Lukaszyk A, Pampuch A, Szmitkowski M, Donati MB, Iacoviello L. Plasminogen activator inhibitor-1 plasma concentration in allergic asthma patients during allergen challenge. Int Arch Allergy Immunol 2007 144 : 240 6.
10. Kowal K, Zukowski S, Moniuszko M, Bodzenta-ukaszyk A. Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients. Folia Histochem Cytobiol 2008 46 : 193 8.
11. Bradding P, Walls AF, Holgate ST. The role of the mast cells in the pathophysiology of asthma. J Allergy Clin Immunol 2006 117 : 1277 84.
12. Ma Z, Jhun B, Oh CK. Upstream stimulating factor-1 mediates the E-box-dependent transcriptional repression of the plasminogen activator inhibitor-1 gene in human mast cells. FEBS Lett 2007 581 : 4485 90.
13. Nakajima T, Inagaki N, Tanaka H et al. Marked increase in CC chemokine gene expression in both human and mouse mast cell transcriptomes following Fcepsilon receptor I cross-linking: an interspecies comparison. Blood 2002 100 : 3861 8.
14. Murakami M, Ikeda T, Saito T et al. Transcriptional regulation of plasminogen activator inhibitor-1 by transforming growth factor-beta, activin A and microphthalmia-associated transcription factor. Cell Signal 2006 18 : 256 65.
15. Wojta J, Kaun C, Zorn G et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood 2002 100 : 517 23.
16. Hara K, Hasegawa T, Ooi H et al. Inhibitory role of eosinophils on cell surface plasmin generation by bronchial epithelial cells: inhibitory effects of transforming growth factor β. Lung 2001 179 : 9 20. (Pubitemid 32667447)
17. Nakao A, Sagara H, Setoguchi Y et al. Expression of Smad7 in bronchial epithelial cells is inversely correlated to basement membrane thickness and airway hyperresponsiveness in patients with asthma. J Allergy Clin Immunol 2002 110 : 873 8.
18. Gomes I, Mathur SK, Espenshade BM, Mori Y, Varga J, Ackerman SJ. Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. J Allergy Clin Immunol 2005 116 : 796 804. (Pubitemid 41400544)
19. Tutluoglu B, Gurel CB, Ozdas SB et al. Platelet function and fibrinolytic activity in patients with bronchial asthma. Clin Appl Thromb Hemost 2005 11 : 77 81. (Pubitemid 40194201)
20. Wygrecka M, Markart P, Ruppert C et al. Cellular origin of pro-coagulant and (anti)-fibrinolytic factors in bleomycin-injured lungs. Eur Respir J 2007 29 : 1105 14.
21. Broide DH. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol 2008 121 : 560 70.
22. Kucharewicz I, Kowal K, Buczko W, Bodzenta-ukaszyk A. The plasmin system in airway remodeling. Thromb Res 2003 112 : 1 7. (Pubitemid 38167577)
23. Liu RM. Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. Antioxid Redox Signal 2008 10 : 303 19.
24. Fu X, Parks WC, Heinecke JW. Activation and silencing of matrix metalloproteinases. Semin Cell Dev Biol 2008 19 : 2 13. (Pubitemid 350235984)
25. Sillaber C, Baghestanian M, Bevec D et al. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J Immunol 1999 162 : 1032 41.
26. Da Silva CA, Reber L, Frossard N. Stem cell factor expression, mast cells and inflammation in asthma. Fundam Clin Pharmacol 2006 20 : 21 39.
27. Ohbayashi H, Shimokata K. Matrix metalloproteinase-9 and airway remodeling in asthma. Curr Drug Targets Inflamm Allergy 2005 4 : 177 81.
28. Lim DH, Cho JY, Miller M, McElwain K, McElwain S, Broide DH. Reduced peribronchial fibrosis in allergen-challenged MMP-9-deficient mice. Am J Physiol Lung Cell Mol Physiol 2006 291 : L265 71.
29. Walters EH, Soltani A, Reid DW, Ward C. Vascular remodelling in asthma. Curr Opin Allergy Clin Immunol 2008 8 : 39 43.
30. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol 2001 107 : 295 301. (Pubitemid 32173907)
31. Feltis BN, Wignarajah D, Zheng L et al. Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma. Am J Respir Crit Care Med 2006 173 : 1201 7.
32. Simcock DE, Kanabar V, Clarke GW, O'Connor BJ, Lee TH, Hirst SJ. Proangiogenic activity in bronchoalveolar lavage fluid from patients with asthma. Am J Respir Crit Care Med 2007 176 : 146 53.
33. Stefansson S, McMahon GA, Petitclerc E, Lawrence DA. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003 9 : 1545 64.
34. Agirbasli M. Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract 2005 59 : 102 6.
35. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000 60 : 5839 47.
36. Ploplis VA, Cornelissen I, Sandoval-Cooper MJ, Weeks L, Noria FA, Castellino FJ. Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. Am J Pathol 2001 158 : 107 17.
37. Chen Y, Budd RC, Kelm RJ Jr., Sobel BE, Schneider DJ. Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol 2006 26 : 1777 83.
38. Richard B, Pichon S, Arocas V et al. The serpin protease nexin-1 regulates vascular smooth muscle cell adhesion, spreading, migration and response to thrombin. J Thromb Haemost 2006 4 : 322 8.
39. Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 2006 4 : 2710 5.
40. Chan JC, Duszczyszyn DA, Castellino FJ, Ploplis VA. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 2001 159 : 1681 8.
41. Hjortland GO, Lillehammer T, Somme S et al. Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells. Exp Cell Res 2004 294 : 130 9.
42. Mulligan-Kehoe MJ, Kleinman HK, Drinane M, Wagner RJ, Wieland C, Powell RJ. A truncated plasminogen activator inhibitor-1 protein blocks the availability of heparin-binding vascular endothelial growth factor A isoforms. J Biol Chem 2002 277 : 49077 89.
43. Cockcroft DW, Davis BE. Mechanisms of airway hyperresponsiveness. J Allergy Clin Immunol 2006 118 : 551 9.
44. Sejima T, Madoiwa S, Mimuro J et al. Protection of plasminogen activator inhibitor-1-deficient mice from nasal allergy. J Immunol 2005 174 : 8135 43.
45. Savov JD, Brass DM, Berman KG, McElvania E, Schwartz DA. Fibrinolysis in LPS-induced chronic airway disease. Am J Physiol Lung Cell Mol Physiol 2003 285 : L940 8.
46. Kjøller L, Kanse SM, Kirkegaard T et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997 232 : 420 9.
47. Marshall LJ, Ramdin LS, Brooks T, Charlton P, Shute JK. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 2003 171 : 2057 65.
48. Poggi M, Paulmyer-Lacroix O, Verdier M et al. Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung. J Thromb Haemost 2007 5 : 2467 75.
49. Eitzman DT, McCoy RD, Zheng X et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996 97 : 232 7.
50. Renckens R, Roelofs JJ, Bonta PI et al. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. Blood 2007 109 : 1593 601.
51. Gyetko MR, Sud S, Chen GH, Fuller JA, Chensue SW, Toews GB. Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection. J Immunol 2002 168 : 801 9.
52. Gyetko MR, Sud S, Chensue SW. Urokinase-deficient mice fail to generate a type 2 immune response following schistosomal antigen challenge. Infect Immun 2004 72 : 461 7.
53. Swaisgood CM, Aronica MA, Swaidani S, Plow EF. Plasminogen is an important regulator in the pathogenesis of a murine model of asthma. Am J Respir Crit Care Med 2007 176 : 333 42.
54. Kathiresan S, Gabriel SB, Yang Q et al. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 2005 112 : 1728 35.
55. Morange PE, Saut N, Alessi MC et al. Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study. Arterioscler Thromb Vasc Biol 2007 27 : 2250 7.
56. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993 268 : 10739 45.
57. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995 92 : 1851 55.
58. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004 150 : 793 8.
59. Chong NW, Codd V, Chan D, Samani NJ. Circadian clock genes cause activation of the human PAI-1 gene promoter with 4G/5G allelic preference. FEBS Lett 2006 580 : 4469 72.
60. Ding J, Nicklas BJ, Fallin MD et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J 2006 152 : 1109 15.
61. Pampuch A, Kowal K, Bodzenta-Lukaszyk A et al. The -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients. Allergy 2006 61 : 234 8.
62. Martínez-Calatrava MJ, Martínez-Larrad MT, Zabena C, González-Sánchez JL, Fernández-Pérez C, Serrano-Ríos M. The 4G/4G PAI-1 genotype is associated with elevated plasma PAI-1 levels regardless of variables of the metabolic syndrome and smoking status. A population-based study in Spanish population. Diabetes Obes Metab 2007 9 : 134 5.
63. Yende S, Angus DC, Ding J et al. for the Health ABC Study. 4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia. Am J Respir Crit Care Med 2007 176 : 1129 37.
64. Roncal C, Orbe J, Rodriguez JA et al. Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension. Cardiovasc Res 2004 63 : 176 85.
65. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998 18 : 20 6.
66. Tsantes AE, Nikolopoulos GK, Bagos PG et al. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost 2007 97 : 907 13.
67. Binder A, Endler G et al. European Meningococcal Study Group. 4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia. J Thromb Haemost 2007 5 : 2049 54.
68. Hermans PW, Hazelzet JA. Plasminogen activator inhibitor type 1 gene polymorphism and sepsis. Clin Infect Dis 2005 41 (Suppl. 7) : S453 8.
69. Eroglu A, Ulu A, Cam R, Akar N. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer. J BUON 2006 11 : 481 4.
70. Jorgenson E, Deitcher SR, Cicek M et al. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history. Prostate 2007 67 : 172 7.
71. Yamada Y, Izawa H, Ichihara S et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002 347 : 1916 23.
72. Martínez-Calatrava MJ, González-Sánchez JL, Zabena C, Martínez-Larrad MT, Luque-Otero M, Serrano-Ríos M. Is the plasminogen activator inhibitor-1 gene a candidate gene predisposing to hypertension? Results from a population-based study in Spain. J Hypertens 2007 25 : 773 7.
73. Loew M, Hoffmann MM, Hahmann H, Maerz W, Brenner H, Rothenbacher D. Genotype combinations of plasminogen activator inhibitor-1 and angiotensin-converting enzyme genes and risk for early onset of coronary heart disease. Eur J Cardiovasc Prev Rehabil 2006 13 : 449 56.
74. Corsetti JP, Ryan D, Moss AJ, Rainwater DL, Zareba W, Sparks CE. Plasminogen activator inhibitor-1 polymorphism (4G/5G) predicts recurrence in nonhyperlipidemic postinfarction patients. Arterioscler Thromb Vasc Biol 2008 28 : 548 54.
75. Cho SH, Hall IP, Wheatley A et al. Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma. J Allergy Clin Immunol 2001 108 : 212 4.
76. Bucková D, Izakovicová Hollá L, Vácha J. Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. Allergy 2002 57 : 446 8.
77. Hizawa N, Maeda Y, Konno S, Fukui Y, Takahashi D, Nishimura M. Genetic polymorphisms at FCER1B and PAI-1 and asthma susceptibility. Clin Exp Allergy 2006 36 : 872 6.
78. Kowal K, Bodzenta-Lukaszyk A, Pampuch A et al. Analysis of -675 4G/5G SERPINE1 and C-159T CD14 polymorphisms in house dust mite-allergic asthma patients. J Investig Allergol Clin Immunol 2008 18 : 284 92.
79. Xu J, Postma DS, Howard TD et al. Major genes regulating total serum immunoglobulin E levels in families with asthma. Am J Hum Genet 2000 67 : 1163 73.
80. Ma Z, Jhun B, Jung SY, Oh CK. Binding of upstream stimulatory factor 1 to the E-Box regulates the 4G/5G polymorphism-dependent plasminogen activator inhibitor 1 expression in mast cells. J Allergy Clin Immunol 2008 121 : 1006 12.
81. Zhan M, Zhou Y, Han ZC. No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro. Int J Hematol 2004 79 : 400 4.
82. Zietz B, Drobnik W, Herfarth H, Buechler C, Scholmerich J, Schaffler A. Plasminogen activator inhibitor-1 promoter activity in adipocytes is not influenced by the 4 G/5 G promoter polymorphism and is regulated by a USF-1/2 binding site immediately preceding the polymorphic region. J Mol Endocrinol 2004 32 : 155 63.
83. White LA, Bruzdzinski C, Kutz SM, Gelehrter TD, Higgins PJ. Growth state-dependent binding of USF-1 to a proximal promoter E box element in the rat plasminogen activator inhibitor type 1 gene. Exp Cell Res 2000 260 : 127 35.
84. 1 transition in human epidermal keratinocytes. J Cell Biochem 2006 99 : 495 507. (Pubitemid 44435566)
85. 2 on specificity and comparison with binding of Myc family members. Nucl Acids Res 1994 22 : 2801 10.
86. Mandola MV, Stoehlmacher J, Muller-Weeks S et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003 63 : 2898 904.
87. Boodhoo A, Wong AM, Williamson D et al. A promoter polymorphism in the central MHC gene, IKRL, influences the binding of transcription factors USF1 and E47 on disease-associated haplotypes. Gene Expr 2004 12 : 1 11. (Pubitemid 39238132)
88. Corre S, Galibert MD. Upstream stimulating factors: highly versatile stress-responsive transcription factors. Pigment Cell Res 2005 18 : 337 48.
89. Nechushtan H, Razin E. Deciphering the early-response transcription factor networks in mast cells. Immunol Today 1998 19 : 441 4.